Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Current Drug Research Reviews is Scopus-indexed (Q2, CiteScore 3.4). It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 2589-9775Verify ISSN ↗2589-9783Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Psychiatry and Mental Health | 279 / 580 | 51st | Q2 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q2, CiteScore 3.4.
Current Drug Research Reviews is Q2 in Psychiatry and Mental Health (rank 279 of 580), by CiteScore 2025.
Current Drug Research Reviews is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 3.4, quartile Q2, 51st percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.487, quartile Q3, with an H-index of 55.
Current Drug Research Reviews is published by Bentham Science Publishers. Its print ISSN is 2589-9775 and its online ISSN is 2589-9783.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Current Drug Research Reviews has an h-index of 20 and a 2-year mean of 1.15 citations per paper (OpenAlex). Its Scopus CiteScore is 3.4, quartile Q2. On 2-year citations it ranks #350 of 570 Scopus journals in Psychiatry and Mental Health.
Current Drug Research Reviews published 50 papers in 2025; its busiest recent year was 2023 with 55. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 92 research articles (2024–2026), authors are most often from India (67%), Brazil (6.1%) and Saudi Arabia (5.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.